Equities

Exelixis Inc

Exelixis Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)34.83
  • Today's Change0.18 / 0.52%
  • Shares traded1.41m
  • 1 Year change+64.14%
  • Beta0.5073
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy6
Outperform8
Hold7
Sell1
Strong Sell0

Share price forecast in USD

The 21 analysts offering 12 month price targets for Exelixis Inc have a median target of 34.00, with a high estimate of 39.00 and a low estimate of 23.00. The median estimate represents a -2.38% decrease from the last price of 34.83.
High12.0%39.00
Med-2.4%34.00
Low-34.0%23.00

Earnings history & estimates in USD

On Oct 29, 2024, Exelixis Inc reported 3rd quarter 2024 earnings of 0.40 per share. This result exceeded the 0.35 consensus of the 13 analysts covering the company and outperformed last year's 3rd quarter results by 0.40.
The next earnings announcement is expected on Feb 04, 2025.
Average growth rate+146.02%
Exelixis Inc reported annual 2023 earnings of 0.65 per share on Feb 06, 2024.
Average growth rate+8.47%
More ▼

Revenue history & estimates in USD

Exelixis, Inc. had 3rd quarter 2024 revenues of 539.54m. This bettered the 490.02m consensus of the 19 analysts covering the company. This was 31.99% above the prior year's 3rd quarter results.
Average growth rate+6.20%
Exelixis, Inc. had revenues for the full year 2023 of 1.83bn. This was 13.60% above the prior year's results.
Average growth rate+18.31%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.